<DOC>
	<DOCNO>NCT00003450</DOCNO>
	<brief_summary>RATIONALE : Inserting p53 gene person 's cancer cell may improve body 's ability fight cancer make cancer sensitive chemotherapy . PURPOSE : Phase I trial study effectiveness gene therapy use p53 gene treat patient advanced recurrent persistent ovarian cancer primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Advanced Recurrent Persistent Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose toxicity intraperitoneal adenoviral p53 gene therapy patient advance , recurrent , persistent ovarian carcinoma . II . Evaluate vector pharmacokinetics biologic efficacy gene transfer , gene expression , cell death patient . III . Determine immunologic response therapy patient . OUTLINE : This dose escalation study adenoviral p53 gene therapy . Patients undergo removal ascites , present , peritoneal cavity follow bolus infusion adenovirus p53 week 3 consecutive week , follow 2 week rest . Treatment continue every 4 week absence disease progression unacceptable toxicity . Patients experience palliative result least stable disease may continue treatment weekly without rest period . Cohorts 3-6 patient treat level adenovirus p53 . The maximum tolerate dose define dose level 2 6 patient experience dose limit toxicity . Patients receive MTD without unacceptable toxicity may continue receive treatment weekly basis . PROJECTED ACCRUAL : Approximately 15-20 patient accrue 16-18 month study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive ovarian epithelial carcinoma primary peritoneal carcinoma time initial laparotomy No histologically confirm noninvasive ovarian malignancy low malignant potential tumor carcinomatosis nonovarian peritoneal site At least three course firstline combination chemotherapy ( platinum paclitaxel ) either persistent recurrent disease If treatment firstline paclitaxel , salvage paclitaxel failure must document prior eligibility Ascites cytologically positive adenocarcinoma gross evidence recurrent disease ascites , gross recurrent disease abdominopelvic wash cytologically positive adenocarcinoma Adequate peritoneal distribution Technetium 99 scan PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Greater 12 week Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT/SGPT great 2.5 time normal No active hepatitis chronic liver failure Renal : Creatinine great 2 mg/dL Other : Not HIV positive No concurrent immunosuppressive disorder No active systemic infection active peritonitis Geographically available followup Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No prior viral base gene therapy treatment p53 direct vaccine No prior gene therapy Chemotherapy : See Disease Characteristics At least 4 week since chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy No concurrent radiotherapy Surgery : At least 4 week since surgery , include surgery perforate bowel , bowel anastamosis , colostomy , ileostomy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>